Vertex Pharmaceuticals SVP & CAO Kristen Ambrose Granted 5,000 RSUs
VERTEX PHARMACEUTICALS INC / MA
Subscribe to track VRTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Form 4 Filing: Vertex Pharmaceuticals Inc ($VRTX) • Insider: Kristen Ambrose (SVP & Chief Accounting Officer) • Transaction Date: August 28, 2026 • Action: Award / Grant (RSU) • Shares: 5,000 Common Stock @ $0.00 • Direct Holdings Post-Transaction: 11,624 shares • Significance: Low (Routine Equity Grant)
Comprehensive Analysis
Executive Summary
On September 1, 2026, Kristen Ambrose, Senior Vice President & Chief Accounting Officer of Vertex Pharmaceuticals Inc ($VRTX), reported an acquisition of 5,000 shares of Common Stock on August 28, 2026.
Transaction Breakdown
- Transaction Code:
A(Grant, award, or other acquisition under Rule 16b-3). - Security Type: Common Stock (Restricted Stock Unit award).
- Shares Acquired: 5,000 shares.
- Transaction Price: $0.00 per share.
- Post-Transaction Beneficial Ownership: 11,624 shares held directly.
- Vesting Terms: According to footnote (1), the restricted stock unit award is scheduled to cliff vest on March 1, 2029.
Market Impact & Significance
This transaction is categorized as Low Significance from an investment and trading perspective because it represents a standard compensatory restricted stock unit (RSU) award rather than an open-market purchase or sale. It reflects routine executive compensation and long-term equity alignment rather than directional market sentiment.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.